Australia's Clarity Pharma gains on tax break to develop cancer platform
17/04/2025 05:32
** Shares of Clarity Pharmaceuticals CU6.AX jumps 12.4% to A$1.885, highest since April 3 ** The radiopharmaceutical company gets R&D tax incentive refund to develop its Targeted Copper Theranostic (TCT) platform to diagnose and treat various cancers ** Co also signs deal for supply of copper-64 isotope, which is used along with copper-67 in TCT platforms ** Despite the day's gains, the stock is down about 55% YTD (Reporting by Jasmeen Ara Shaikh in Bengaluru) ((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial